Complement activation in thrombotic microangiopathy

Hamostaseologie

Volumn 33, Issue 2, 2013, Pages 96-104

  Karpman, D ^a   Tati, R ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Complement

Indexed keywords

ARGININE CARBOXYPEPTIDASE; C REACTIVE PROTEIN; CD59 ANTIGEN; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; CLUSTERIN; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4 BINDING PROTEIN; COMPLEMENT FACTOR H; DECAY ACCELERATING FACTOR; ECULIZUMAB; FIBRINOGEN; INTERLEUKIN 1ALPHA; LECTIN; MEMBRANE COFACTOR PROTEIN; PROPERDIN; THROMBOMODULIN; VITRONECTIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTERIAL WALL THICKENING; ARTERIOLE; ARTICLE; CAPILLARY; COMPLEMENT ACTIVATION; ENDOTHELIUM CELL; ESCHERICHIA COLI INFECTION; HEMOLYTIC UREMIC SYNDROME; HUMAN; INNATE IMMUNITY; LEUKOCYTE MIGRATION; NEUTROPHIL CHEMOTAXIS; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

BLOOD COAGULATION FACTORS; BLOOD VESSELS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MODELS, IMMUNOLOGICAL; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOSIS;

EID: 84881518113     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/HAMO-12-12-0025     Document Type: Article

References (107)

1. Monnens L, Molenaar J, Lambert PH et al. The complement system in hemolytic-uremic syndrome in childhood. Clin Nephrol 1980; 13: 168-171.
2. Warwicker P, Goodship TH, Donne RL et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998; 53: 836-844.
3. Ying L, Katz Y, Schlesinger M et al. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet 1999; 65: 1538-1546.
4. Loos M. The complement system: activation and control. Curr Top Microbiol Immunol 1985; 121: 7-18.
5. Garred P, Honore C, Ma YJ et al. MBL2, FCN1, FCN2 and FCN3-The genes behind the initiation of the lectin pathway of complement. Mol Immunol 2009; 46: 2737-2744.
6. Roos A, Bouwman LH, van Gijlswijk-Janssen DJ et al. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 2001; 167: 2861-2868.
7. Law SK, Levine RP. Interaction between the third complement protein and cell surface macromolecules. Proc Natl Acad Sci 1977; 74: 2701-2705.
8. Podack ER, Biesecker G, Muller-Eberhard HJ. Membrane attack complex of complement: generation of high-affinity phospholipid binding sites by fusion of five hydrophilic plasma proteins. Proc Natl Acad Sci 1979; 76: 897-901.
9. Pangburn MK. Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement. Immunopharmacology 2000; 49: 149-157.
10. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001; 60: 831-846.
11. Besbas N, Karpman D, Landau D et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006; 70: 423-431.
12. Karpman D, Sartz L, Johnson S. Pathophysiology of typical hemolytic uremic syndrome. Semin Thromb Haemostas 2010; 36: 575-585.
13. Obrig TG, Karpman D. Shiga toxin pathogenesis: kidney complications and renal failure. Curr Topics Microbiol Immunol 2012; 357: 105-136.
14. Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008; 23: 1957-1972.
15. Furlan M, Robles R, Galbusera M et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolyticuremic syndrome. N Engl J Med 1998; 339: 1578-1584.
16. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
17. Manuelian T, Hellwage J, Meri S et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 2003; 111: 1181-1190.
18. Vaziri-Sani F, Holmberg L, Sjöholm AG et al. Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome. Kidney Int 2006; 69: 981-988.
19. Ståhl AL, Vaziri-Sani F, Heinen S et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 2008; 111: 5307-5315.
20. Van de Kar NC, Monnens LA, Karmali MA et al. Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome. Blood 1992; 80: 2755-2764.
21. Louise CB, Obrig TG. Shiga toxin-associated hemolytic- uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1 beta, and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect Immun 1991; 59: 4173-4179.
22. Karpman D, Papadopoulou D, Nilsson K et al. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood 2001; 97: 3100-3108.
23. Ruiz-Torres MP, Casiraghi F, Galbusera M et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost 2005; 93: 443-452.
24. Platt JL, Vercellotti GM, Lindman BJ et al. Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection. J Exp Med 1990; 171: 1363-1368.
25. Bossi F, Peerschke EI, Ghebrehiwet B et al. Crosstalk between the complement and the kinin system in vascular permeability. Immunol Lett 2011; 140: 7-13.
26. Nachman RL, Hajjar KA, Silverstein RL et al. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med 1986; 163: 1595-1600.
27. Saadi S, Holzknecht RA, Patte CP et al. Complement- mediated regulation of tissue factor activity in endothelium. J Exp Med 1995; 182: 1807-1814.
28. Acosta J, Qin X, Halperin J. Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Curr Pharm Des 2004; 10: 203-211.
29. Langeggen H, Pausa M, Johnson E et al. The endothelium is an extrahepatic site of synthesis of the seventh component of the complement system. Clin Exp Immunol 2000; 121: 69-76.
30. Lozada C, Levin RI, Huie M et al. Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1. Proc Natl Acad Sci USA 1995; 92: 8378-8382.
31. Kilgore KS, Shen JP, Miller BF et al. Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol 1995; 155: 1434-1441.
32. Van den Berg RH, Faber-Krol MC, Sim RB et al. The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells. J Immunol 1998; 161: 6924-6930.
33. Kilgore KS, Flory CM, Miller BF et al. The membrane attack complex of complement induces interleukin- 8 and monocyte chemoattractant protein- 1 secretion from human umbilical vein endothelial cells. Am J Pathol 1996; 149: 953-961.
34. Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 1994; 179: 985-992.
35. Fischetti F, Tedesco F. Cross-talk between the complement system and endothelial cells in physiologic conditions and in vascular diseases. Autoimmunity 2006; 39: 417-428.
36. Hamilton KK, Hattori R, Esmon CT et al. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990; 265: 3809-3814.
37. Monsinjon T, Gasque P, Chan P et al. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J 2003; 17: 1003-1014.
38. Kerr H, Richards A. Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome. Immunobiology 2012; 217: 195-203.
39. Karpman D, Kahn R. The contact/kinin and complement systems in vasculitis. APMIS Suppl 2009: 48-54.
40. Bossi F, Fischetti F, Pellis V et al. Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex. J Immunol 2004; 173: 6921-6927.
41. Dobrina A, Pausa M, Fischetti F et al. Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo. Blood 2002; 99: 185-192.
42. Morigi M, Galbusera M, Gastoldi S et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 2011; 187: 172-180.
43. Roumenina LT, Frimat M, Miller EC et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood 2012; 119: 4182-4191.
44. Roumenina LT, Jablonski M, Hue C et al. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 2009; 114: 2837-2845.
45. Frenette PS, Johnson RC, Hynes RO et al. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci 1995; 92: 7450-7454.
46. Del Conde I, Cruz MA, Zhang H et al. Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005; 201: 871-879.
47. Karpman D, Manea M, Vaziri-Sani F et al. Platelet activation in hemolytic uremic syndrome. Semin Thromb Hemost 2006; 32: 128-145.
48. Endresen GK, Mellbye OJ. Studies on the binding of complement factor C3 to the surface of human blood platelets. Haemostasis 1984; 14: 269-280.
49. Sandvik T, Endresen GK, Forre O. Studies on the binding of complement factor C4 in human platelets. Complement activation by means of cold agglutinins. Int Arch Allergy Appl Immunol 1984; 74: 152-157.
50. Nunez D, Charriaut-Marlangue C, Barel M et al. Activation of human platelets through gp140, the C3d/EBV receptor (CR2). Eur J Immunol 1987; 17: 515-520.
51. Vik DP, Fearon DT. Cellular distribution of complement receptor type 4 (CR4): expression on human platelets. J Immunol 1987; 138: 254-258.
52. Cosgrove LJ, d'Apice AJ, Haddad A et al. CR3 receptor on platelets and its role in the prostaglandin metabolic pathway. Immunol Cell Biol 1987; 65 (Pt 6): 453-460.
53. Peerschke EI, Ghebrehiwet B. Platelet membrane receptors for the complement component C1q. Semin Hematol 1994; 31: 320-328.
54. Zimmerman TS, Kolb WP. Human platelet-initiated formation and uptake of the C5-9 complex of human complement. J Clin Invest 1976; 57: 203-211.
55. Polley MJ, Nachman RL. Human complement in thrombin-mediated platelet function: uptake of the C5b-9 complex. J Exp Med 1979; 150: 633-645.
56. Polley MJ, Nachman RL. Human platelet activation by C3a and C3a des-arg. J Exp Med 1983; 158: 603-615.
57. Dixon RH, Rosse WF. Mechanism of complementmediated activation of human blood platelets in vitro: comparison of normal and paroxysmal nocturnal hemoglobinuria platelets. J Clin Invest 1977; 59: 360-368.
58. Nicholson-Weller A, March JP, Rosen CE et al. Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system. Blood 1985; 65: 1237-1244.
59. Tschopp J, Jenne DE, Hertig S et al. Human megakaryocytes express clusterin and package it without apolipoprotein A-1 into alpha-granules. Blood 1993; 82: 118-125.
60. Yu GH, Holers VM, Seya T et al. Identification of a third component of complement-binding glycoprotein of human platelets. J Clin Invest 1986; 78: 494-501.
61. Morgan BP. Isolation and characterization of the complement-inhibiting protein CD59 antigen from platelet membranes. Biochem J 1992; 282 (Pt 2): 409-413.
62. Vaziri-Sani F, Hellwage J, Zipfel PF et al. Factor H binds to washed human platelets. J Thromb Haemost 2005; 3: 154-162.
63. Licht C, Pluthero FG, Li L et al. Platelet-associated complement factor H in healthy persons and patients with atypical HUS. Blood 2009; 114: 4538-4545.
64. Kenney DM, Davis AE, 3rd. Association of alternative complement pathway components with human blood platelets: secretion and localization of factor D and beta 1H Globulin. Clin Immunol Immunopathol 1981; 21: 351-363.
65. Ståhl AL, Svensson M, Morgelin M et al. Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome. Blood 2006; 108: 167-176.
66. Ståhl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coliinduced hemolytic uremic syndrome. Blood 2011; 117: 5503-5513.
67. Sartz L, Olin AI, Kristoffersson AC et al. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome. J Immunol 2012; 188: 2030-2037.
68. Dong JF, Moake JL, Nolasco L et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033-4039.
69. Kelton JG, Warkentin TE, Hayward CP et al. Calpain activity in patients with thrombotic thrombocytopenic purpura is associated with platelet microparticles. Blood 1992; 80: 2246-2251.
70. Jimenez JJ, Jy W, Mauro LM et al. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease. Br J Haematol 2001; 112: 81-90.
71. Williams JD, Czop JK, Abrahamson DR et al. Activation of the alternative complement pathway by isolated human glomerular basement membrane. J Immunol 1984; 133: 394-399.
72. Hindmarsh EJ, Marks RM. Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction or removal of overlying endothelial cells. J Immunol 1998; 160: 6128-6136.
73. Bevan HS, Slater SC, Clarke H et al. Acute laminar shear stress reversibly increases human glomerular endothelial cell permeability via activation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol 2011; 301: F733-F742.
74. Dong JF, Moake JL, Bernardo A et al. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem 2003; 278: 29633-29639.
75. Louise CB, Obrig TG. Specific interaction of Escherichia coli O157:H7-derived Shiga-like toxin II with human renal endothelial cells. J Infect Dis 1995; 172: 1397-1401.
76. Robson WL, Leung AK, Fick GH et al. Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome. Nephron 1992; 62: 296-299.
77. Thurman JM, Marians R, Emlen W et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4: 1920-1924.
78. Orth D, Khan AB, Naim A et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009; 182: 6394-6400.
79. Lapeyraque AL, Malina M, Fremeaux-Bacchi V et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011; 364: 2561-2563.
80. Menne J, Nitschke M, Stingele R et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012; 345: e4565.
81. Kielstein JT, Beutel G, Fleig S et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 2012; 27: 3807-3815.
82. Loos S, Ahlenstiel T, Kranz B et al. An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 2012; 55: 753-759.
83. Delvaeye M, Noris M, De Vriese A et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 345-357.
84. Ståhl AL, Kristoffersson A, Olin AI et al. A novel mutation in the complement regulator clusterin in recurrent hemolytic uremic syndrome. Mol Immunol 2009; 46: 2236-2243.
85. Zipfel PF, Mache C, Muller D et al. DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody- positive form of hemolytic uremic syndrome. Pediatr Nephrol; 2010: 25: 2009-2019.
86. Brackman D, Sartz L, Leh S et al. Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis. Nephrol Dial Transplant 2011; 26: 3399-3403.
87. Zuber J, Fakhouri F, Roumenina LT et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8: 643-657.
88. Zuber J, Le Quintrec M, Krid S et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012; 12: 3337-3354.
89. Crawley JT, de Groot R, Xiang Y et al. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood 2011; 118: 3212-3221.
90. Reti M, Farkas P, Csuka D et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 2012; 10: 791-798.
91. Noris M, Ruggenenti P, Perna A et al. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. J Am Soc Nephrol 1999; 10: 281-293.
92. Mant MJ, Cauchi MN, Medley G. Thrombotic thrombocytopenic purpura: report of a case with possible immune etiology. Blood 1972; 40: 416-421.
93. Weisenburger DD, O'Conner ML, Hart MN. Thrombotic thrombocytopenic purpura with C'3 vascular deposits: report of a case. Am J Clin Pathol 1977; 67: 61-63.
94. Chapin J, Weksler B, Magro C et al. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol; 157: 772-774.
95. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344: 1058-1066.
96. Heinen S, Hartmann A, Lauer N et al. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 2009; 114: 2439-2447.
97. Nilsson SC, Sim RB, Lea SM et al. Complement factor I in health and disease. Mol Immunol 2011; 48: 1611-1620.
98. Cardone J, Le Friec G, Kemper C. CD46 in innate and adaptive immunity: an update. Clin Exp Immunol 2011; 164: 301-311.
99. Seya T, Okada M, Matsumoto M et al. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP). Mol Immunol 1991; 28: 1137-1147.
100. Conway EM. Thrombomodulin and its role in inflammation. Semin Immunopathol 2012; 34: 107-125.
101. Petersen SV, Thiel S, Jensen L et al. Control of the classical and the MBL pathway of complement activation. Mol Immunol 2000; 37: 803-811.
102. Gigli I, Fujita T, Nussenzweig V. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Proc Natl Acad Sci USA 1979; 76: 6596-6600.
103. Medof ME, Iida K, Mold C et al. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med 1982; 156: 1739-1754.
104. Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984; 160: 1558-1578.
105. Podack ER, Preissner KT, Muller-Eberhard HJ. Inhibition of C9 polymerization within the SC5b-9 complex of complement by S-protein. Acta Pathol Microbiol Immunol Scand Suppl 1984; 284: 89-96.
106. Davies A, Simmons DL, Hale G et al. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 1989; 170: 637-654.
107. Bokisch VA, Muller-Eberhard HJ. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest 1970; 49: 2427-2436.